These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 31695326)
1. Design, synthesis, and biological study of 4-[(2-nitroimidazole-1 Cheng W; Wang S; Yang Z; Tian X; Hu Y Drug Des Devel Ther; 2019; 13():3079-3089. PubMed ID: 31695326 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia. Cheng W; Zhu S; Ma X; Qiu N; Peng P; Sheng R; Hu Y Eur J Med Chem; 2015 Jan; 89():826-34. PubMed ID: 25462282 [TBL] [Abstract][Full Text] [Related]
3. Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia. Cheng W; Yuan Y; Qiu N; Peng P; Sheng R; Hu Y Bioorg Med Chem; 2014 Dec; 22(24):6796-805. PubMed ID: 25468044 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886 [TBL] [Abstract][Full Text] [Related]
6. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo. Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358 [TBL] [Abstract][Full Text] [Related]
7. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity. Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919 [TBL] [Abstract][Full Text] [Related]
8. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents. Sadek MM; Serrya RA; Kafafy AH; Ahmed M; Wang F; Abouzid KA J Enzyme Inhib Med Chem; 2014 Apr; 29(2):215-22. PubMed ID: 23402383 [TBL] [Abstract][Full Text] [Related]
9. Design and Synthesis of Vandetanib Derivatives Containing Nitroimidazole Groups as Tyrosine Kinase Inhibitors in Normoxia and Hypoxia. Wei H; Li D; Yang X; Shang H; Fan S; Li Y; Song D Molecules; 2016 Dec; 21(12):. PubMed ID: 27983649 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and Anticancer Activity of Novel Indole Derivatives as Dual EGFR/SRC Kinase Inhibitors. Olgen S; Kaleli SNB; Karaca BT; Demirel UU; Bristow HK Curr Med Chem; 2024; 31(24):3798-3817. PubMed ID: 37365789 [TBL] [Abstract][Full Text] [Related]
11. Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors. Zhang HQ; Gong FH; Li CG; Zhang C; Wang YJ; Xu YG; Sun LP Eur J Med Chem; 2016 Feb; 109():371-9. PubMed ID: 26826581 [TBL] [Abstract][Full Text] [Related]
12. Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors. Li SN; Xu YY; Gao JY; Yin HR; Zhang SL; Li HQ Bioorg Med Chem; 2015 Jul; 23(13):3221-7. PubMed ID: 26003342 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2. Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290 [TBL] [Abstract][Full Text] [Related]
14. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking. Elkamhawy A; Farag AK; Viswanath AN; Bedair TM; Leem DG; Lee KT; Pae AN; Roh EJ Bioorg Med Chem Lett; 2015 Nov; 25(22):5147-54. PubMed ID: 26475520 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers. Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor. Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors. Zhou Z; He J; Yang F; Pan Q; Yang Z; Zheng P; Xu S; Zhu W Bioorg Chem; 2021 Jul; 112():104848. PubMed ID: 33819737 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors. Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528 [TBL] [Abstract][Full Text] [Related]